In 2013, payment coding for molecular diagnostics tests focused on the purpose of the test performed rather than the method used. Specific information is available for molecular cytogenomic testing and cystic fibrosis carrier screening and diagnostic testing.
For more information on MoPath codes, especially those relevant to cystic fibrosis and cytogenomics testing, see the Laboratory Coding and Payment resources.
Molecular pathology (MoPath) codes provide a consistent framework for laboratories to label molecular diagnostics tests, enabling payers (i.e., Medicare, private insurance companies) to properly identify and bill for services. Until recently, these codes were based on the type of test being performed and not the analyte being analyzed. This made it difficult for payers to identify and properly reimburse molecular diagnostics tests. The new MoPath codes set out by the American Medical Association (AMA) Current Procedural Terminology (CPT) replace the previous methodology-based "stacking" MoPath codes with analyte-specific codes.
On January 1, 2013, the “stacking” codes (CPT 83890-83914; 88384-88386) were retired and are no longer available for provider billing. Therefore, laboratories are now required to use the new MoPath codes when billing for molecular diagnostic services.
MoPath codes are categorized into Tier 1 and Tier 2 codes:
Gapfilling is one of two methodologies that the Centers for Medicare and Medicaid Services (CMS) can employ to set the Medicare payment rate for a new CPT code that is reimbursed under the Clinical Laboratory Fee Schedule (CLFS). The second is crosswalking, which involves benchmarking payment for the new code to the same rate for comparable, existing test(s) or code(s).
When CMS decides to gapfill payment for a new code, the local Medicare Administrative Contractors (MACs) are responsible for determining the appropriate fee schedule amounts in the first year. The map below shows a breakdown of MACs by jurisdication (as of December 2012). In the second year, CMS calculates a national payment rate based on the median of these local fee schedule amounts. This median payment rate is referred to as the National Limitation Amount (NLA).
It is up to the discretion of each MAC to identify and use the most appropriate methodologies to set a gapfill payment amount. However, the following information should be considered in the rate setting process, if available:
Because Medicaid and commercial payers often use Medicare as a benchmark when developing their own payment policies, the outcome of gapfilling initiatives at the MAC level could influence payment rates set by other payers as well. Some private payers may also undertake activities similar to gapfill
Cannot serve request to /content/illumina-marketing/emea/en_GB/clinical/diagnostics/reimbursement/education.html on this server